TARS2
Threonine--tRNA ligase, mitochondrial
Also known as: FLJ12528, SYTM_HUMAN, TARSL1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9BW92
- Gene
- TARS2
- Ensembl
- ENSG00000143374
- Chromosome
- 1
- Canonical length
- 718 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a member of the class-II aminoacyl-tRNA synthetase family. The encoded protein is a mitochondrial aminoacyl-tRNA synthetase. Alternative splicing results in multiple transcript variants. A related pseudogene has been identified on chromosome 4. [provided by RefSeq, Dec 2012]
Canonical amino-acid sequenceUniProt
718 residues, UniProt reviewed canonical sequence.
>Q9BW92|TARS2
1 MALYQRWRCL RLQGLQACRL HTAVVSTPPR WLAERLGLFE ELWAAQVKRL ASMAQKEPRT
61 IKISLPGGQK IDAVAWNTTP YQLARQISST LADTAVAAQV NGEPYDLERP LETDSDLRFL
121 TFDSPEGKAV FWHSSTHVLG AAAEQFLGAV LCRGPSTEYG FYHDFFLGKE RTIRGSELPV
181 LERICQELTA AARPFRRLEA SRDQLRQLFK DNPFKLHLIE EKVTGPTATV YGCGTLVDLC
241 QGPHLRHTGQ IGGLKLLSNS SSLWRSSGAP ETLQRVSGIS FPTTELLRVW EAWREEAELR
301 DHRRIGKEQE LFFFHELSPG SCFFLPRGTR VYNALVAFIR AEYAHRGFSE VKTPTLFSTK
361 LWEQSGHWEH YQEDMFAVQP PGSDRPPSSQ SDDSTRHITD TLALKPMNCP AHCLMFAHRP
421 RSWRELPLRL ADFGALHRAE ASGGLGGLTR LRCFQQDDAH IFCTTDQLEA EIQSCLDFLR
481 SVYAVLGFSF RLALSTRPSG FLGDPCLWDQ AEQVLKQALK EFGEPWDLNS GDGAFYGPKI
541 DVHLHDALGR PHQCGTIQLD FQLPLRFDLQ YKGQAGALER PVLIHRAVLG SVERLLGVLA
601 ESCGGKWPLW LSPFQVVVIP VGSEQEEYAK EAQQSLRAAG LVSDLDADSG LTLSRRIRRA
661 QLAHYNFQFV VGQKEQSKRT VNIRTRDNRR LGEWDLPEAV QRLVELQNTR VPNAEEIFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TARS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 30 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 30 nTPM
- tongue: 29 nTPM
- liver: 24 nTPM
- heart muscle: 19 nTPM
- parathyroid gland: 17 nTPM
- tonsil: 14 nTPM
Single-cell type
- endometrial luminal cells: 50 nCPM
- esophageal apical cells: 47 nCPM
- myonuclei: 38 nCPM
- cytotrophoblasts: 36 nCPM
- epididymal basal cells: 29 nCPM
- hepatocytes: 27 nCPM
Immune cell
- NK-cell: 33 nTPM
- T-reg: 31 nTPM
- basophil: 31 nTPM
- eosinophil: 31 nTPM
- non-classical monocyte: 29 nTPM
- memory B-cell: 29 nTPM
Brain region
- pons: 19 nTPM
- white matter: 18 nTPM
- thalamus: 17 nTPM
- cerebral cortex: 17 nTPM
- midbrain: 17 nTPM
- basal ganglia: 17 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about TARS2.
Disease | AllUniProt
Conditions TARS2 is implicated in, by any mechanism.
- Combined oxidative phosphorylation deficiency 21 (COXPD21) MIM:615918
Disease | GeneticClinVar
18 pathogenic / likely-pathogenic of 349 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Combined oxidative phosphorylation defect type 21
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.84
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.77
- DepMap mean gene effect
- -0.48
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 16% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- threonyl-tRNA aminoacylation
- mitochondrial threonyl-tRNA aminoacylation
Molecular functions
- aminoacyl-tRNA deacylase activity
- ATP binding
- protein homodimerization activity
- threonine-tRNA ligase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Aminoacyl-tRNA synthetase, class II (G/ P/ S/T)
- Threonine-tRNA ligase, class IIa
- TGS
- Anticodon-binding
- Aminoacyl-tRNA synthetase, class II
- Beta-grasp domain superfamily
- TGS-like
- Threonyl/alanyl tRNA synthetase, SAD
- Threonyl/alanyl tRNA synthetase, class II-like, putative editing domain superfamily
- Threonine-tRNA ligase catalytic core domain
- Anticodon-binding domain superfamily
- Class II Aminoacyl-tRNA synthetase/Biotinyl protein ligase (BPL) and lipoyl protein ligase (LPL)
- Threonine-tRNA ligase, class IIa, anticodon-binding domain
- tRNA synthetase class II core domain (G, H, P, S and T)
- TGS domain
- Anticodon binding domain
- Threonyl and Alanyl tRNA synthetase second additional domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TARS2 as an antibody target. Whether an autoantibody or antibody against TARS2 could matter depends on whether native TARS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TARS2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TARS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...